At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement.

Our approach integrates innovative target identification using advanced predictive models, antibody engineering and optimization for high specificity and affinity, and drug conjugate development leveraging cutting-edge linker and payload technologies. We focus on rapidly transitioning from preclinical research to clinical proof of concept in indications with high unmet medical needs.

Committed to translating breakthrough science into tangible medical solutions, we advance our therapeutic candidates to key development milestones before forging strategic partnerships. Through co-development, out-licensing, and R&D collaborations, we maximize the potential of our innovations to bring life-changing treatments to patients worldwide.

With a robust pipeline and world-class expertise, we are shaping the future of medicine to deliver groundbreaking and durable treatment solutions for patients in need.